IDTA (IDenta) Debt-to-Revenue : 0.47 (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is IDenta Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

IDenta's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.03 Mil. IDenta's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.66 Mil. IDenta's annualized Revenue for the quarter that ended in Sep. 2024 was $1.47 Mil. IDenta's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.47.

IDenta Debt-to-Revenue Historical Data

The historical data trend for IDenta's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDenta Debt-to-Revenue Chart

IDenta Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.54

0.33

0.37

0.66

0.75

IDenta Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial															-	0.43	0.44	0.49	0.47

Competitive Comparison of IDenta's Debt-to-Revenue

For the Diagnostics & Research subindustry, IDenta's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDenta's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDenta's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where IDenta's Debt-to-Revenue falls into.

IDenta Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

IDenta's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.061	+	0.725)	/	1.052
	=	0.75

IDenta's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.03	+	0.662)	/	1.468
	=	0.47

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

IDenta Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of IDenta's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

IDenta Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDenta Corp (OTCPK:IDTA) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bethlehem Road 120, Jerusalem, ISR, 9342001

Website

https://www.identa-corp.com

IDenta Corp is a detection and forensic science company. The firm, through its subsidiary, is engaged in the business of developing products to test for the presence of illegal drugs and explosives for law enforcement agencies, the military, government agencies, and other organizations. Its product portfolio includes Drug testing kits, Explosive testing kits, Precursors of Drugs Test kits, portable sniffers, Bullet-hole testing kits, and others. The Company currently sells its products to law enforcement organizations in the following countries Indonesia, Argentina, Poland, France, USA, Spain, India, the United Kingdom, Ghana, Nigeria, Australia, Russia, Israel, Canada, Germany, Italy, and Portugal. The Company also sells to retail markets in the United States, Italy, and South Africa.